Norovirus Diagnostics Market

The rise in the prevalence of norovirus infection will act as major driver that will results in the expansion of Norovirus Diagnostics market’s growth

Norovirus Infection Diagnostics Market Segmented By Rapid Test Kits, PCR Kits, ELISA-based kits Product

Industry: Healthcare

Published Date: December-2022

Format: PPT*, PDF, EXCEL

Delivery Timelines: Contact Sales

Number of Pages: 245

Report ID: PMRREP25924

Report Price

$ 4900*

Buy Now

Norovirus Diagnostics Market Outlook (2023-2033)

Worldwide revenue from the Norovirus Diagnostics Market stands at US$ 54.1 Mn in 2022, with the global market estimated to surge ahead at a CAGR of 8.7% to reach a valuation of US$ 134.0 Mn by the end of 2033.

Attributes Key Insights

Norovirus Diagnostics Market Size (2022)

US$ 54.1 Mn

Projected Market Value (2033)

US$ 134.0 Mn

Global Market Growth Rate (2023-2033)

8.7% CAGR

Market Share of Top 5 Countries

49.0%

Sales Analysis of the Global Market from 2016 to 2022 Vs Market Outlook for 2023 to 2033

The global market for norovirus diagnostics recorded a historic CAGR of 5.7% in the last 6 years from 2016 to 2022. Norovirus diagnostics market contributes nearly 0.2% to the global virus testing diagnostic kits market valued at 22.6 Bn in 2022.

The stomach and intestinal virus known as norovirus is extremely contagious. Direct or indirect contact with an infected person is all that is necessary for it to spread. In crowded places like hospitals, schools, and daycare facilities, it can spread swiftly. It affects the stomach and digestive tract frequently. Since the norovirus can be acquired from consuming tainted food, it can potentially cause food poisoning.

The expansion of the market's growth will be mostly attributed to the increase in the prevalence of norovirus infections. The increasing cost of healthcare is a significant factor affecting the market for norovirus diagnostics market. The market for norovirus diagnostics will also develop as a result of improvements in medical technology, rising awareness-raising efforts by both public and private organisations, and expanding government support. The market for norovirus diagnostics will expand at a faster rate as a result of additional reasons such the rising desire for efficient diagnostics and high consumption of junk food. Additionally, the market for norovirus diagnostics will grow as a result of increased disposable income and changing lifestyles.

The prevalence of norovirus is increasing. With an estimated 685 million cases annually, norovirus is the most common cause of acute gastroenteritis, according to the CDC. Children under the age of five are affected by about 200 million cases, with about 50,000 projected deaths per year, mostly in developing countries.

There is an increase in the need for quick diagnostics to find norovirus. The use of various norovirus diagnostic tools, including PCR and fast testing, to identify norovirus infections has increased. This is a result of these products' improved norovirus detection capabilities.

Even a small number of norovirus virions can cause infection, making the norovirus sickness extremely contagious (1-10 virions particles). Only RT-PCR, which is reliable and sensitive, is now available for virus detection.

The global market is thus likely to show high growth over the coming years at a CAGR of 8.7% and reach a global market size of US$ 134.0 Mn by 2033.

What Factors will Drive the Market to Grow over Forecast Duration?

Rising Incidence of Norovirus Disease

The extensive use of opportunistic focus in the worldwide norovirus diagnostics market is a result of the sophisticated techniques adopted by leading participants or manufacturers. Medical device businesses have increased their R&D spending due to the rising incidence of norovirus disease. As major corporations raise their efforts in new advanced product development that is more sensitive and swift, the market for norovirus infection diagnostics is projected to increase in the near future.

Additionally, the growing acceptance and commercialization of norovirus diagnostic in poorer nations is opening up a wealth of opportunities.

Another indicator of the impact on the market for norovirus testing is the growth of diagnostics labs. A beneficial effect on sales and revenue for manufacturers is one of the advantages of the rising emergence of diagnostics labs. The Indian diagnostics market is made up of 16% of diagnostics chains and 47% of independent diagnostic centres, according to a survey. The market is driven by these evolving diagnostics laboratories.

Is there Any Impact on the Growth of the Norovirus Diagnostics Market?

Lack of Awareness about Norovirus

The market for norovirus diagnostics is being constrained by both prevalent social and economic factors. The burden of norovirus infection predominance in poor nations and the lack of knowledge about the signs that precede norovirus infection have slowed the growth of the norovirus diagnostics sector.

Furthermore, underdiagnosis of norovirus has negatively impacted patient health and wellbeing because of the internalised shame associated with not contacting doctors for norovirus illness owing to ignorance. Norovirus infection symptoms include cramps, nausea, vomiting, diarrhoea, and low-grade fever. Numerous other infections can potentially give these symptoms. Thus, there is a great likelihood that the illness will be incorrectly identified. Furthermore, most people dismiss these minor symptoms and diagnosis. Therefore, a lack of understanding could prevent the market for diagnosing norovirus infection from expanding.

Additionally, the emergence of potential competitors in the market has led to pricing competition among producers, which has functioned as a barrier to norovirus diagnostics uptake.

Country-wise Insights

Why is the U.S. Market Booming?

“Increasing R&D Spending”

The U.S. accounted for around 79.7% market share in the North America norovirus diagnostics market in 2022. Due to the high prevalence of norovirus infection, the existence of significant companies, and increased R&D spending, the country holds a significant market share for norovirus diagnostics. The expansion of the market is also anticipated to be fueled by the increase in measures taken by governments and authorities to develop healthcare systems. The American government has taken steps to strengthen its regulatory and research capacities. For instance, the approval rate has grown by 25% in 2020, according to the U.S. FDA's premarket approval database.

Will Germany Be a Lucrative Market for Medical Wellness Market?

“Fitness is Highly Valued by German Population”

Germany held around 23.8% market share of the Europe norovirus diagnostics market in 2022. The growth of this market in this region is mainly driven by the presence of major players and collaborations by them for the development of new products.

•For instance, In December 2020, Altona Diagnostics GmbH launched AltoStar Norovirus RT-PCR Kit 1.5, an automated in-vitro diagnostic test for the detection of norovirus genogroup I (GI) and II (GII).

•In March 2018, R-Biopharm AG collaborated with Bosch Healthcare Solutions for the development of an all-in-one platform for molecular diagnosis.

How is China Emerging as a Prominent Market for Medical Wellness?

“The Chinese Workforce Anticipates Financial Benefits”

China held a market share of about 46.3% of the East Asia norovirus diagnostics market in 2022. Manufacturers are putting their efforts into increasing their strategic global presence, specialist knowledge, and cutting-edge technological skills, which makes norovirus diagnostics products more widely available in China.

Category-wise Insights

Which Diagnostic products is Driving the Growth of the Global Market?

“Varied Range of Services”

Rapid Test Kits are anticipated to hold the largest market share at 57.6% in 2023 according to projections. Rapid test kits are expected to increase profitably, with a CAGR of 10.1%, at the end of the projection period. A method like ELISA is ineffective for real-time diagnosis and is insufficient for the detection of norovirus. Polymerase chain reaction (PCR) is currently a widely utilised method for detection to get around this. Companies are developing approaches that are quicker and more refined. This will driving the segment's growth as a result.

Which End User is Dominating the Global Market in 2023?

Growing Demand for Infection Diagnosis”

Diagnostic Laboratories held the largest value share in the global market in 2022 and is expected to further grow with a CAGR of 9.5% over the forecast duration. The growing number of infections require diagnosis of the issue by utilising diagnostic testing kits at large number. Diagnostic Labs are thus the preferable centers in comparison to other facilities to conduct these testing.

Competition Landscape

Key firms are concentrating on new product manufacturing and expansion in developing regions. The expansion, introduction, and approval of new products are all part of the leading manufacturers' strategies to increase their market presence.

Key instances include:

  • In April 2020, Meridian Biosciences acquired Exalenz Bioscience for approximately US$ 89 Mn
  • In April 2018, R-Biopharm AG received the FDA approval for RIDA-GENE Norovirus GI/GII for the detection and differentiation of norovirus genogroup I (GI) and II (GII).

Similarly, recent developments related to companies manufacturing norovirus diagnostics products have been tracked by the team at Persistence Market Research, which is available in the full report.

Norovirus Diagnostics Industry Report Scope

Attribute Details

Forecast Period

2023-2033

Historical Data Available for

2016-2022

Market Analysis

USD Million for Value

Key Countries Covered

  • U.S.
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Russia
  • BENELUX
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Turkey
  • GCC Countries
  • North Africa

Key Market Segments Covered

  • Product
  • End User
  • Region

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Key Companies Profiled

  • Abbott
  • R-Biopharm AG
  • ELITechGroup AG
  • Danaher Corporation (Cepheid)
  • Meridian Bioscience Inc.
  • Eiken Chemical Co.
  • Altona Diagnostics GmbH
  • CerTest Biotec S.L
  • Elisabeth Pharmacon, Spol. S Ro
  • Qiagen
  • Altona Diagnostics GmbH
  • Eiken Chemical Co

Customization & Pricing

Available upon Request

Key Segments Covered in Norovirus Diagnostics Industry Research

By Product

  • Rapid Test Kits
  • PCR Kits
  • ELISA based kits

By End-User

  • Hospitals
  • Diagnostics Labs
  • Clinics

Region

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

To know more about delivery timeline for this report Contact Sales

Companies Covered in This Report

  • Abbott
  • R-Biopharm AG
  • Cepheid
  • Luminex Corporation
  • Meridian Bioscience
  • ELITechGroup
  • Biomérieux SA
  • CerTest Biotec S.L.
  • Elisabeth Pharmacon, Spol. S Ro
  • Qiagen
  • Altona Diagnostics GmbH
  • Eiken Chemical Co

Frequently Asked Questions

The global market is currently valued at around US$ 54.1 Mn in 2022.

Sales of the market are set to witness growth at a CAGR of 8.7% and be valued at around US$ 134.0 Mn by 2033.

Demand for the market increased at a 5.7% CAGR from 2016 to 2022.

The U.S., Germany, Canada, U.K., and Japan account for most demand for norovirus diagnostics, currently holding around 49.0% market share.

The U.S. accounts for around 79.7% share of the North American market in 2022.

Latin America will grow at a CAGR rate of 11.1% over the forecast period.

China held a market share of about 46.3% of the East Asia norovirus diagnostics market in 2022.

Germany held around 23.8% market share of the Europe norovirus diagnostics market in 2022.

UK market is expected to grow at a 7.5% CAGR during the forecast period.

The market in India is set to expand at a 13.1% CAGR over the forecast period.

Thank you for taking time to visit our website, click like if you found the information on this page useful?

This site uses cookies, including third-party cookies, that help us to provide and improve our services.
Google translate